Eur J Obstet Gynecol Reprod Biol by Baca, Katharyn M. et al.
Vitamin D metabolic loci and vitamin D status in Black and White 
pregnant women
Katharyn M. Bacaa, Manika Govilb, Joseph M. Zmudaa,c, Hyagriv N. Simhand,e, Mary L. 
Marazitab,c,f, and Lisa M. Bodnara,d,e,*
aDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 
Pittsburgh, PA, 15261, USA
bCenter for Craniofacial and Dental Genetics, Department of Oral Biology, School of Dental 
Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
cDepartment of Human Genetics, Graduate School of Public Health, University of Pittsburgh, 
15261, USA
dDepartment of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, 
University of Pittsburgh, 300 Halket Street, Pittsburgh, PA, 15213, USA
eMagee-Womens Research Institute, Pittsburgh, PA, 15213, USA
fClinical and Translational Science Institute, School of Medicine, University of Pittsburgh, 
Pittsburgh, PA, 15213, USA
Abstract
Background—Several candidate genes and genome wide association studies have reported 
significant associations between vitamin D metabolism genes and 25-hydroxyvitamin D. Few 
studies have examined these relationships in pregnancy.
Objective—We evaluated the relationship between maternal allelic variants in three vitamin D 
metabolism genes and 25-hydroxyvitamin D (25(OH)D) concentration in pregnancy.
Study design—In two case-control studies, samples were drawn from women who delivered at 
Magee Womens Hospital in Pittsburgh, PA from 1999 to 2010 and twelve recruiting sites across 
the United States from 1959 to 65. For 882 Black and 1796 White pregnant women from these 
studies, 25(OH)D concentration was measured and single nucleotide polymorphisms (SNPs) were 
genotyped 50 kilobases up- and down-stream in three genes (VDR, GC, and CYP27B1). Using 
multivariable linear regression, we estimated the associations between allelic variation of each 
locus and log-transformed 25(OH)D concentration separately by race and study group. Meta-
analysis was used to estimate the association across the four groups for each SNP.
*Corresponding author at: University of Pittsburgh, Graduate School of Public Health, 130 DeSoto St, Pittsburgh, PA, 15261, USA. 
bodnar@edc.pitt.edu (L.M. Bodnar). 
Disclosure statement
The authors report no conflict of interest.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ejogrb.2017.11.013.
HHS Public Access
Author manuscript
Eur J Obstet Gynecol Reprod Biol. Author manuscript; available in PMC 2019 July 18.
Published in final edited form as:
Eur J Obstet Gynecol Reprod Biol. 2018 January ; 220: 61–68. doi:10.1016/j.ejogrb.2017.11.013.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results—Minor alleles of several variants in VDR, GC, and CYP27B1 were associated with 
differences in log-transformed 25(OH)D concentration compared to the corresponding major 
alleles [beta, 95% confidence intervals (CI)]. The meta-analysis confirmed the associations for 
differences in log-transformed 25(OH)D by allelic loci for one intron VDR variant [rs2853559 
0.08 (0.02, 0.13), p < 0.01] and a variant in the GC flanking region [rs13150174: 0.04 (0.02, 0.07), 
p < 0.01], and a GC missense mutation [rs7041 0.05 (0.01, 0.09), p < 0.01]. The meta-analysis 
also revealed possible associations for SNPs in linkage disequilibrium with variants in the VDR 3-
prime untranslated region, another GC missense variant (rs4588), and a variant of the 3-prime 
untranslated region of CYP27B1.
Conclusion—We observed associations between VDR, GC, and CYP27B1 variants and 
maternal 25-hydroxyvitamin D concentration. Our results provide additional support for a possible 
role of genetic variation in vitamin D metabolism genes on vitamin D status during pregnancy.
Keywords
Vitamin D deficiency; 25-Hydroxy vitamin d; Vitamin d metabolic loci; Vitamin D binding protein 
gene; Vitamin D receptor gene; 1 alpha-hydroxylase gene; Genetic variation; Vitamin D; VDR; 
CYP27B1; GC
Introduction
One in four pregnant women in the U.S. has suboptimal vitamin D status [1–3], as defined 
by serum 25-hydroxyvitamin D (25(OH) D) concentrations <50 nmol/L [4]. Non-Hispanic 
Black women are 3–5 times as likely as non-Hispanic White women to be deficient in 
vitamin [5,6]. The widespread deficiency and racial/ethnic gap in its prevalence is 
concerning because of the associations between low 25(OH)D and the increase risk of 
offspring rickets [7], preterm birth [8], preeclampsia [9], small-for-gestational age birth [10], 
childhood asthma [11], and type 1 diabetes mellitus [12]. Therefore, understanding factors 
that influence vitamin D status is of clinical and public health importance.
Single nucleotide polymorphisms (SNPs) in several genes in the vitamin D metabolic 
pathway contribute to circulating 25(OH)D concentration [13]. These genes include the 
vitamin D binding (GC), cytochrome p450 27B1 (CYP27B1), and the vitamin D receptor 
genes (VDR). While there have been many studies exploring the contribution of genetic 
variation in these genes to vitamin D status among non-pregnant adults [13–15], there is a 
paucity of data among pregnant women and particularly among racially/ethnically diverse 
women.
Pregnancy is accompanied by important alterations in vitamin D metabolism, including 
increasing circulation of DBP [16], enhanced hydroxylation of 25(OH)D to 1,25(OH)2D in 
kidneys and other cells and organs [17], and transportation of 25(OH)D into the placenta 
[18]. Therefore, determining whether genetic variation of key vitamin D metabolism genes 
is associated with 25(OH) D concentration in pregnancy is important. Thus, our objective 
was to evaluate the relationship between common SNPs in the GC, CYP27B1, and VDR 
genes and maternal serum 25(OH)D concentrations in two large pregnancy study groups of 
Black and White mothers.
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Materials and methods
For this study, we used data and stored samples from two pregnancy case-control studies on 
vitamin D and adverse birth outcomes: Epidemiology of Vitamin D Study (EVITA) and 
Collaborative Perinatal Project (CPP). Both studies were approved by the University of 
Pittsburgh Institutional Review Board. Both studies have been described in detail elsewhere 
[19,20]. In brief, eligibility criteria for EVITA included singleton pregnancies with an 
available banked serum sample from aneuploidy screening at ≤20 weeks at the hospital’s 
Center for Medical Genetics and Genomics, and delivered at Magee-Womens Hospital of 
University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania (total of 12,861 eligible 
pregnancies). We selected a randomly-sampled set of controls of 2327 eligible women for 
25(OH)D assessment in the case-control study, and from this group all term pregnancies 
without preeclampsia of non-Hispanic White (n = 1394) and non-Hispanic Black (n = 353) 
women were used in the current analysis.
In CPP, more than 55,000 women at 12 U.S medical centers in 1959–65 were enrolled. The 
cohort of eligible women for the parent study included women with singleton pregnancies, 
no preexisting conditions (pregestational diabetes, hypertension, or cardiovascular disease), 
and a banked serum sample at <26 week (n = 28,429). We then randomly selected a 
subcohort of 2986 eligible women. From this group, we selected 1076 White and 882 Black 
women with non-preeclamptic term deliveries for serum 25(OH)D assay. In both studies, 
racial/ethnic groups other than White and Black were excluded from genotyping because of 
small samples.
Maternal serum samples in CPP were collected at ≤26 weeks of gestation and stored for 40 
years at −20 °C with no recorded thaws. EVITA samples were collected at ≤20 weeks of 
gestation and were stored at −80 °C for 2–12 years. 25(OH)D has been proven to be highly 
stable. No loss of 25(OH)D has been noted after leaving uncentrifuged blood up to 72 h at 
24 °C, after storage of serum for years at 20 °C, after exposure to ultraviolet light, or after up 
to 11 freeze-thaw cycles [21]. A pilot study in the CPP samples compared 25(OH)D in these 
serum with serum frozen for ≤2 years and found that 25(OH)D is unlikely to show 
significant degradation [22].
Sera from both study groups were sent to the same Vitamin D External Quality Assessment 
Scheme certified laboratory. Samples were assayed for total 25-hydroxyvitamin D 
(25(OH)D) [25(OH) D2 + 25(OH)D3] using liquid-chromatography-tandem mass 
spectrometry based on National Institute of Standards and Technology standards [23]. Intra- 
and the inter-assay variations were ≤9.6% and ≤10.9%, respectively. Vitamin D deficiency 
was defined as 25 (OH)D <50 nmol/L.
Using the International HapMap database (Phase 3) [24], tagging SNPs with minor allele 
frequency of 10% or more were identified for a region spanning 50 kilobases up- and 
downstream of each candidate gene. The tagging SNPs were selected based on a reference 
population of the HapMap “Utah residents with Northern and Western European ancestry” 
(CEU), and then supplemented with additional SNPs from the HapMap “Americans of 
African Ancestry in Southwest USA” (ASW) population to adequately capture variation 
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across the candidate genes within our diverse study samples. In total, 499 SNPs were 
selected: 39 for CYP27B1, 126 for GC, 206 for VDR. We also genotyped 128 ancestry 
informative markers (AIMs) in both Black and White women, which is a validated set of 
markers to identify common populations in America that can be determined using analysis 
in STRUCTURE 2.3.4 (Stanford, CA) [25–29].
Serum was thawed, and potential contaminants and inhibitors were removed using Qiagen 
kits (QIAGEN, Valencia, CA). The resulting serum product was whole genome amplified 
using REPLi-g midi kit (QIAGEN, Valencia, CA). The QuantStudio 12 K Flex platform 
(Life Technologies, Carlsbad, CA) was used to genotype the selected SNPs. Genotypes were 
called using the TaqMan Genotyper software (Version 1.3.1, Grand Island, NY) and visual 
assessment of the data was used for confirmation.
Potential confounding variables came from the perinatal database in EVITA and in-person 
interviews for CPP. Both studies included data on pre-pregnancy body mass index (<18.5, 
18.5–24.9, 25–29.9, ≥30), preexisting diabetes (yes, no), maternal education (<12 years, 12 
years, and >12 years), marital status (single, married), maternal age (<20, 20–29, ≥30), 
parity, and season of blood draw (winter (December–February), spring (March–May), 
summer (June–August), or fall (September–November)). Season of sampling was considered 
a potential confounder due to the seasonal effects of UVB radiation on the vitamin D 
endocrine system [30]. Gestational age was based on best obstetric estimate comparing 
menstrual dating and ultrasound estimates in EVITA and on the mother’s report of the first 
day of her last menstrual period in CPP since ultrasound was not available in the 1960s. Data 
on provider type were available for women in EVITA. A composite socioeconomic status 
score was available for CPP, which combines education, occupation, and family income data 
[31].
Statistics
To minimize confounding due to population substructure, genetic ancestry and self-reported 
race were used to categorize mothers as Black or White [29]. First, individual ancestral 
proportions were calculated using an analysis of AIMs in STRUCTURE 2.3.4 (Stanford, 
CA) [25–28]. An ad hoc statistic based on the rate change in the log probability of data 
between clusters was used to identify two subgroups in each study [32]. Individuals who 
self-identified as White but had a >50% probability of belonging to ASW were reassigned to 
Black race. However, all self-reported Black mothers were assigned to Black race unless 
they had a 100% probability of being CEU.
Data-quality control steps were performed using PLINK software (Version 1.07; Boston, 
MA) [33,34]. Samples and markers with call rates <80% were omitted from further 
analyses. All SNPs included in the analysis had a call rate >80%, minor allele frequency 
>0.05 and were in Hardy–Weinberg equilibrium (P > 0.00001) (Supplementary Fig. 1). For 
SNPs that passed quality control, a test of variance was conducted to determine if genotype 
missingness was significantly different among the four study groups (White mothers in 
EVITA, Black mothers in EVITA, White mothers in CPP, White mothers in CPP) or by race, 
study, or chromosome.
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Analyses were completed separately by study (CPP and EVITA) and race/ethnicity (Black or 
White) groups. For each race-study group, we calculated the geometric mean of 25(OH)D 
(nmol/L) by allele and tested for differences using nonparametric trend tests. Associations 
between minor allele and log-transformed 25(OH)D concentration (to reduce skewness of 
the data which resulted in normally distributed residuals) were further examined in 
univariable and multivariable linear regression models. We first modeled functional SNPs in 
parsimonious models by removing potential confounders from the model if their exclusion 
did not change the main exposure point estimate by ≥10%. Using these methods, we 
adjusted for batch number (in EVITA only), year drawn (in EVITA only), site (CPP), season 
of blood draw, sample age, and maternal age. All models for Black mothers were adjusted 
for percent African ancestry. Other variables did not change the estimate >10% (BMI, 
education, insurance, smoking status, diabetes status, and parity). The final model satisfied 
the ANOVA goodness of fit test compared to other models. For comparability, we used the 
same model for tagging SNPs. All associations were adjusted for multiple comparisons and 
linkage disequilibrium (LD) using ‘LD adjusted’ Bonferroni corrected p-value thresholds 
[35]. LD of two SNPs characterized dependent heritability which was measured using 
PLINK software. The resulting associations were weighted by the inverse of their variances 
to summarize across studies and race in a meta-analysis. Lastly, HaploReg software (version 
4.1) was used to find if these studied SNPs were in LD with functional SNPs [36]. A 
sensitivity analysis on the ancestry informative markers was conducted by rerunning 
analysis on only self-reported race.
Results
Supplemental Fig. 1 flowchart summarizes the final sample sizes, and final number of SNPs 
for each candidate gene after data quality control. Missingness did not differ by chromosome 
(p > 0.05) or the two study samples (p > 0.05). However, SNPs for Black mothers were more 
likely to be missing than SNPs in White mothers (p < 0.05). More specifically, SNPs in 
Black mothers in CPP were more likely to be missing and SNPs in White mothers in EVITA 
were less likely to be missing compared to other race-study groups.
Compared with mothers from EVITA, mothers from CPP completed less education (83% vs. 
48% with high school education or less), had a higher prevalence of smoking (66% vs. 
12%), and lower prevalence of obesity (4% vs. 23% BMI ≥ 30). On average, women in CPP 
were younger (24 ± 5.6 years) than women in EVITA (29 ± 6.3 years). Blood samples in 
EVITA were collected earlier in gestation than CPP (15 weeks versus 19 weeks). Black 
mothers in CPP completed fewer years of education and were leaner, multiparous, and were 
more likely to smoke compared with Black mothers in EVITA. Similarly, White mothers in 
CPP also completed fewer years of education, were more likely to have normal BMI, 
multiparous, and smoke compared with White mothers in EVITA (Table 1).
The prevalence of vitamin D deficiency was higher in Black mothers than White mothers in 
both study populations (68% in CPP and 53% in EVITA vs. 38% in CPP and 9% in EVITA, 
respectively). The geometric means and 95% confidence intervals of 25(OH)D were 36.6 
nmol/L (35, 38 nmol/L) and 45 nmol/L (42, 48 nmol/L) among Black mothers in CPP and 
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EVITA, respectively, and 54 nmol/L (52, 56 nmol/L) and 73 nmol/L (72, 74 nmol/L) among 
White mothers in CPP and EVITA, respectively.
Several intron variants of VDR were associated with significant differences in log-25(OH)D 
concentrations in the univariate and multivariable analysis (Table 2; Data Brief article). An 
intron variant of the 5-prime untranslated region (rs11168293) was associated with increased 
log-25(OH)D compared with the major allele among Black mothers in EVITA (beta 0.22 
95%CI 0.10, 0.35 p < 0.001). This association remained significant after Bonferroni 
adjustment. For other SNPs, the associations in the multivariable analyses attenuated in 
significance after adjustment for multiple comparisons. However, one variant (rs2853559) 
had a trend of increased log-25(OH)D concentration in the multivariable analysis and 
showed a significant difference in log-25(OH)D by allelic loci in the meta-analysis (Fig. 1). 
Although not significant in the multivariable analysis, the meta-analysis revealed 
associations for four intron variants (rs7971418, rs11574114, rs2408876 and rs4760650). 
Variants rs7971418 (rs2853562, rs9729, rs78783628, rs739837) and rs11574114 
(rs11574139, rs2853563, rs3858733, rs11574119) had strong LD (R2 >0.90) with variants in 
the VDR 3-prime untranslated region.
Several SNPs in the non-coding and flanking regions of GC were associated with significant 
differences in log-25(OH)D concentrations in the univariate and multivariable analysis 
(Table 3; Data Brief article). A minor allele of the flanking region (rs13150174) and a 
missense mutation (rs7041) were associated with increased log-25(OH)D compared with the 
major allele only among White mothers in EVITA (p <0.001), however significance of the 
associations attenuated after Bonferroni adjustment. The metaanalysis showed an overall 
significant trend of increased log-25 (OH)D concentration for the minor alleles of 
rs13150174 and rs7041 across the four study-race groups (Fig. 1). Additionally, several 
minor alleles in GC were associated with a difference in log-25(OH)D in the meta-analysis, 
including the following: a missense variant (rs4588), three intron variants (rs705120, 
rs72860546, and rs1526692) and two variants of the flanking region (rs56003670 and 
rs842877). Variants rs13150174, rs7041, rs4588, and rs72860546 were in LD with several 
intron variants of GC, while rs1526692 and rs56003670 were in LD with variants of the 
flanking regions, and rs705120 was in LD with a missense mutation (rs7041).
One intron variant in the flanking region of CYP27B1 (rs10877011) was associated with 
increased log-25(OH)D concentration among Black mothers in EVITA in the multivariable 
analysis but significance was lost after Bonferroni adjustment (beta 0.15 95%CI 0.04, 0.26 p 
<0.01) (Table 4; Data Brief article). The meta-analysis showed a variant of the 3-prime 
untranslated region (rsl2318065) and two intron variants (rsl2582311 and rs701007) were 
associated with differences in log-25(OH)D (Fig. 1). These variants were not in LD with 
functional variants in CYP27B1.
The sensitivity analysis showed no differences in the results for VDR, GC, and CYP27B1 
variants (data not shown) when using just self-reported maternal race.
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Comment
Maternal genotype of seven SNPs in VDR, three SNPs in GC, and one SNP in the flanking 
region of CYP27B1 were associated with differences in log-25(OH)D concentration during 
pregnancy. Of these associations, one SNP in VDR remained significant after adjustment for 
LD and multiple comparisons (rs11168293). The meta-analytic approach confirmed the 
associations for one SNP in VDR (rs2853559) and two SNPs in GC (rs13150174 and 
rs7041). The meta-analytic approach also revealed possible relationships for each of the 
three genes. Variants in VDR were in LD with variants in the 3-prime untranslated region of 
VDR.
SNPs in VDR may influence serum 25(OH)D by changing the rate at which 25(OH)D is 
hydroxylated [37] either directly or via a negative feedback loop. In a study of 354 White 
pregnant women, maternal 25(OH)D did not vary by VDR genotype. However, this study 
included only four SNPs–three of which were included in our analysis [38]. These variants, 
rs7975232, rs1544410, and rs731236, were not associated with 25(OH)D concentration in 
our study. However, one SNP, rs7971418, had strong LD (R2 > 0.90) with 4 functional 
variants in the VDR 3-prime untranslated region in our study. Variants in this region may be 
regulating mRNA stability [39], thereby the variant may be modulating VDR expression. 
Additionally, our study measured associations between log-25 (OH)D and several minor 
alleles of intronic variants in VDR that are in LD with variants in the VDR 3-prime 
untranslated region. These findings support a possible role of VDR with 25(OH)D 
concentration in pregnancy.
We genotyped common SNPs across the GC region that encodes DBP which is a protein that 
controls the bioavailability of free 25 (OH)D [40], and therefore may be a surrogate marker 
for 25(OH)D status. The minor allele for rs7041 was associated with increased 25(OH)D 
and rs4588 was associated with decreased 25(OH)D in our study. We are not aware of 
published reports examining allelic variation within GC and serum 25(OH)D concentrations 
among pregnant women. Our results for rs7041 do contrast with literature that show 
25(OH)D concentrations are reduced with the rs7041 minor allele among ethnically diverse 
samples of non-pregnant adults; while our finding on rs4588 is consistent with this literature 
[41–46]. It is possible that changes that occur in pregnancy, including increased circulation 
of DBP from 7% to 152% [16] and enhanced hydroxylation of 25(OH)D to 1,25(OH)2D 
[17], may explain these differences in study results. It is also possible that our results for 
rs7041 may be influenced by the heterogeneity measured between the race-study groups.
The CYP27B1 gene encodes an enzyme called 1-alpha-hydroxylase (1α-hydroxylase), 
which converts 25(OH)D from diet and sunlight to its active form, 1,25-dihydroxyvitamin 
D3. Variations in this gene is shown to be associated with lower 25(OH)D [47], perhaps due 
to changes in enzymatic activity [48]. In a cohort of 222 White, diabetic pregnant women, 
the minor genotype of rs10877012 was more common in women with 25(OH)D > 50 
nmol/L at 24 weeks of gestation compared to the major genotype (p = 0.01) [37]. Our study 
did not confirm their results in the univariable, multivariable, or meta-analysis.
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By setting thresholds for missing data by SNP and by samples in the quality control steps, 
we reduced the likelihood of spurious data due to failed assays and poor-quality samples, 
respectively. If these quality control steps were avoided, differences in DNA quality could 
have biased towards one genotype or another [49]. After quality control steps, there were 
differences in missingness of SNP data by race and study-race group, but it did not differ by 
chromosome. Since samples were randomly distributed on each genotyping array the 
chances of systemic bias were minimized. The differences in missingness may indicate that 
there were differences in DNA quality between studies. It is possible that we may not have 
detected all associations due to the loss of some SNPs. However, it seems unlikely that SNP 
missingness yielded false-positive associations. Nonetheless, future genome wide 
association studies are needed to identify additional genes and alleles for 25(OH)D 
concentrations in pregnant women. Furthermore, since we only studied two ancestral groups, 
our findings may not be generalizable to other ancestral groups. Despite a proportion of 
women being recategorized into the Black ancestry group, our sensitivity analysis showed 
no significant difference in findings if we only used self-reported race in our study. There 
were non-genetic factors that may have also affected serum 25(OH)D concentration during 
pregnancy, such as supplement use, that were not measured and adjusted for in the analysis. 
If factors differed by vitamin D metabolic loci, it is possible the observed results could have 
been biased but this seems unlikely. Our study also has notable strengths including the large 
sample of Black and White pregnancies and utilization of ancestry informative markers 
rather than sole reliance on self-reported race. In comparison to previous studies, our 
approach of genotyping multiple tagging SNPs in two large and diverse samples had greater 
power to more comprehensively assess candidate gene variation.
If our results linking SNPs in VDR, GC, or CYP27B1 with 25(OH)D concentration among 
pregnant women are confirmed, then genotyping of common allelic variants may play an 
important role in vitamin D metabolism in pregnancy. This knowledge may ultimately help 
us to better understand how the vitamin D endocrine system may contribute to vitamin D 
deficiency in pregnancy by identifying functional variants.
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Refer to Web version on PubMed Central for supplementary material.
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25(OH)D 25-hydroxyvitamin D
CYP27B1 1 alpha-hydroxylase
GC vitamin D binding protein
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chr chromosome
SNP single nucleotide polymorphisms
25(OH)D 25-hydroxyvitamin D
BMI body-mass index
ICD-9 International Classification of Diseases
OR odds ratio
CI confidence interval
ASW Americans of African Ancestry in Southwest USA
CEU Utah residents with Northern and Western European ancestry
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Fig. 1. 
Meta-analysis for associations between minor alleles of SNPs in VDR, GC, and CYP27B1 
and log-25(OH)D across CPP and EVITA studies and maternal race groups.
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